Altamira Therapeutics Ltd.
CYTONASDAQHealthcare
$0.30
+$0.30(+100.00%)
Market Cap$1133556
P/E Ratio—
52W High$0.4158
52W Low$0.3
Altamira Therapeutics Ltd. (CYTO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CYTO · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2024Report Date: Sep 24, 2024EPS Actual
-$1.99
Est. -$2.38 · +16.6%
Revenue
—
Fiscal Period
Q3 FY2024
FY ends December
Report Date
Sep 24, 2024
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
CYTO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2025 | May 16, 2025 | — | — | — | — | — | — |
| ▲ Q3 FY2024 | Sep 24, 2024 | -$2.38 | -$1.99 | +16.6% | — | — | — |
| — Q3 FY2024 | Aug 15, 2024 | -$2.38 | -$2.39 | -0.2% | — | — | — |
| ◌ Q2 FY2024 | May 16, 2024 | — | — | — | — | — | — |
| ◌ Q4 FY2023 | Dec 11, 2023 | — | — | — | — | — | — |
| ◌ Q3 FY2023 | Sep 12, 2023 | — | — | — | — | $0.06B | — |
| — Q3 FY2023 | Aug 15, 2023 | — | -$14.40 | — | $0.00B | — | — |
| — Q2 FY2023 | May 16, 2023 | — | -$3.13 | — | — | $0.06B | — |
Q2 FY2025
May 16, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2024
Sep 24, 2024Beat
EPS Actual
-$1.99
EPS Est.
-$2.38
EPS Surpr.
+16.6%
Revenue
—
Q3 FY2024
Aug 15, 2024
EPS Actual
-$2.39
EPS Est.
-$2.38
EPS Surpr.
-0.2%
Revenue
—
Q2 FY2024
May 16, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2023
Dec 11, 2023
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2023
Sep 12, 2023
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2023
Aug 15, 2023
EPS Actual
-$14.40
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2023
May 16, 2023
EPS Actual
-$3.13
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $-0.44 | $-0.44 | $-0.44 | 1 |
| Q1 FY2027 | $-0.41 | $-0.41 | $-0.41 | 1 |
| Q4 FY2026 | $-0.46 | $-0.46 | $-0.46 | 1 |
| Q3 FY2026 | $-0.43 | $-0.43 | $-0.43 | 1 |
| Q2 FY2026 | $-0.41 | $-0.41 | $-0.41 | 1 |
| Q1 FY2026 | $-0.45 | $-0.45 | $-0.45 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q3 FY2024 | Sep 24, 2024 | +16.6% | $0.67 | $0.70 | +4.49% |
| ▲ Q3 FY2024 | Aug 15, 2024 | -0.2% | $0.92 | $1.01 | +9.81% |
| — Q3 FY2023 | Aug 15, 2023 | — | $7.46 | $7.60 | +1.88% |
| — Q2 FY2023 | May 16, 2023 | — | $18.72 | $17.99 | -3.87% |
| — Q2 FY2023 | Apr 11, 2023 | — | $41.40 | $26.40 | -36.23% |
| — Q4 FY2022 | Nov 30, 2022 | — | $121.20 | $113.00 | -6.77% |
| — Q3 FY2022 | Sep 30, 2022 | — | $116.72 | $115.96 | -0.65% |
| — Q2 FY2022 | Apr 12, 2022 | — | $664.00 | $456.00 | -31.33% |
Q3 FY2024+4.49%
Report Date
Sep 24, 2024
EPS Beat/Miss
+16.6%
Price Before
$0.67
Price After
$0.70
Q3 FY2024+9.81%
Report Date
Aug 15, 2024
EPS Beat/Miss
-0.2%
Price Before
$0.92
Price After
$1.01
Q3 FY2023+1.88%
Report Date
Aug 15, 2023
EPS Beat/Miss
—
Price Before
$7.46
Price After
$7.60
Q2 FY2023-3.87%
Report Date
May 16, 2023
EPS Beat/Miss
—
Price Before
$18.72
Price After
$17.99
Q2 FY2023-36.23%
Report Date
Apr 11, 2023
EPS Beat/Miss
—
Price Before
$41.40
Price After
$26.40
Q4 FY2022-6.77%
Report Date
Nov 30, 2022
EPS Beat/Miss
—
Price Before
$121.20
Price After
$113.00
Q3 FY2022-0.65%
Report Date
Sep 30, 2022
EPS Beat/Miss
—
Price Before
$116.72
Price After
$115.96
Q2 FY2022-31.33%
Report Date
Apr 12, 2022
EPS Beat/Miss
—
Price Before
$664.00
Price After
$456.00
Avg Beat Reaction+7.15%
Beat Rate2 / 8 quarters
Largest Move-36.23% (Q2 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CYTO ends December
Altamira Therapeutics Ltd. (CYTO) most recently reported earnings on September 24, 2024 for Q3 FY2024, posting EPS of $-1.99 — beating the analyst consensus of $-2.38 by +16.6%. The next CYTO earnings date is expected around September 1, 2026.
Each quarter, investors track CYTO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CYTO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CYTO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CYTO earnings · 5 questionsAltamira Therapeutics Ltd.'s next earnings report is expected around September 1, 2026. CYTO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CYTO historically reports after market close (AMC).
CYTO earnings datewhen is CYTO earningsCYTO next earnings datewhen does CYTO report earningsCYTO earnings calendar
▸ Source: FMP · Altamira Therapeutics Ltd. SEC filings · US GAAP · Altamira Therapeutics Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026